Lih-Jen Su, MS

Publications

• The synergistic activity of VGFR inhibition via pazopanib plus docetaxel in bladder cancer cells.AACR 100 Annual Scientific Conference,Denver, April,2009
• Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner Thomas W. Flaig, Lih-Jen Su, Caroline McCoach, Yuan Li, David Raben*, Marileila Varella-Garcia and Lynne T. Bemis BJU International, vol 103 issue12,P1729-1737,2009
• A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer Thomas W. Flaig 1 *, Michael Glod? 1, Daniel Gustafson 2, Adrie van Bokhoven 3, Yuzhen Tao 4, Shandra Wilson 5, Lih-Jen Su 1, Yuan Li 1, Gail Harrison 1, Rajesh Agarwal 6, E. David Crawford 5, M. Scott Lucia 3, Michael Pollak 4 A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer Thomas W. Flaig 1 *, Michael Glod? 1, Daniel Gustafson 2, Adrie van Bokhoven 3, Yuzhen Tao 4, Shandra Wilson 5, Lih-Jen Su 1, Yuan Li 1, Gail Harrison 1, Rajesh Agarwal 6, E. David Crawford 5, M. Scott Lucia 3, Michael Pollak 4 The Prostate, Dec 2009
• The role of beta tubulin3 in bladder cancer resistance to taxane treatment.University of Colorado Cancer Center, Summer cancer research felloship 2009. Kristen French, Lih-Jen Su, Xiaoping Yang, Thomas flaig
• study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer 1. Thomas W. Flaig1,*, 2. Michael Glodé1, 3. Daniel Gustafson2, 4. Adrie van Bokhoven3, 5. Yuzhen Tao4, 6. Shandra Wilson5, 7. Lih-Jen Su1, 8. Yuan Li1, 9. Gail Harrison1, 10. Rajesh Agarwal6, 11. E. David Crawford5, 12. M. Scott Lucia3, 13. Michael Pollak4 Article first published online: 1 FEB 2010 DOI: 10.1002/pros.21118 The Prostate Volume 70, Issue 8, pages 848–855, 1 June 2010
• Manuscript #: URL-D-10-00691R3 Title: "Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells" Article Type: Medical Oncology Submitted to: UROLOGY
• Kessler ER, Su LJ, Yang X, Altubas C, Li C, Flaig TW, Kavanagh B. "Oral glycine reduces radiation-induced HIF1 alpha and enhances tumor growth delay in a prostate cancer xenograft." 2013 American Society of Clinical Oncology Genitourinary Symposium, February 14, 2013 in Orlando, FL.
• Kessler ER, Li X, Su LJ, Yang X, Morales D, Anduha M, Chronister N, Wacker M, Flaig TW, Glode LM, Lam ET. “Phase II trial of acai juice product in biochemically recurrent prostate cancer.” 2013 American Society of Clinical Oncology Genitourinary Symposium, February 14, 2013 in Orlando, FL.
• Pazopanib Synergizes with Docetaxel in the Treatment of Bladder Cancer Cells Yuan Li, Xiaoping Yang, Lih-Jen Su, and Thomas W. Flaig UROLOGY 78: 233.e7–233.e13, 2011. ©
• Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer Xiaoping Yang1,5, Elizabeth Kessler1, Lih-Jen Su1, Andrew Thorburn2,3, Arthur E. Frankel6, Yuan Li1, Francisco G. La Rosa3,5, Jingping Shen4, Chuan-Yuan Li4,5, Marileila Varella-Garcia1,5, L. Michael Glod
  e1,5, and Thomas W. Flaig1,5 Clin Cancer Res; 19(1) January 1, 2013
• miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2 Xiaoping Yang,1 Lynne Bemis,1,2 Lih-Jen Su,1 Dexiang Gao,3,4 and Thomas W. Flaig1 BioResearch Open Access Volume 1, Number 2, 2012
• Cho SK, Emoto K, Su LJ, Yang X, Flaig TW, Park W. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J Biomed Nanotechnol. 2014 Jul;10(7):1267-76. PubMed PMID: 24804547
• http://dx.doi.org/10.1117/12.2238365
• Walsh P, Dorner A, Duke RC, Su LJ, Glode LM. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer Inst. 1995 Jun 7;87(11):809-16. PubMed PMID: 7791230
• Lidor YJ, Lee WE, Nilson JH, Maxwell IH, Su LJ, Brand E, Glode LM. In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines. Am J Obstet Gynecol. 1997 Sep;177(3):579-85. PubMed PMID: 9322627
• Lee LA, Walsh P, Prater CA, Su LJ, Marchbank A, Egbert TB, Dellavalle RP, Targoff IN, Kaufman KM, Chorzelski TP, Jablonska S. Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family. J Invest Dermatol. 1999 Aug;113(2):146-51. PubMed PMID: 10469295
• Dellavalle RP, Egbert TB, Marchbank A, Su LJ, Lee LA, Walsh P. CUSP/p63 expression in rat and human tissues. J Dermatol Sci. 2001 Oct;27(2):82-7. PubMed PMID: 11532371
• Dellavalle RP, Walsh P, Marchbank A, Grayson TE, Su LJ, Parker ER, DeGregori J, Penheiter K, Aszterbaum M, Epstein EH Jr, Lee LA. CUSP/p63 expression in basal cell carcinoma. Exp Dermatol. 2002 Jun;11(3):203-8. PubMed PMID: 12102658
• Marchbank A, Su LJ, Walsh P, DeGregori J, Penheiter K, Grayson TB, Dellavalle RP, Lee LA. The CUSP DeltaNp63alpha isoform of human p63 is downregulated by solar-simulated ultraviolet radiation. J Dermatol Sci. 2003 Jun;32(1):71-4. PubMed PMID: 12788532
• Arthur C, Flaig T, Su LJ, Denney R, Barnes F, Glodé LM. The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines. Ultrasonics. 2007 Mar;46(1):68-73. PubMed PMID: 17173946
• Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 Apr;25(2):139-46. PubMed PMID: 17077998
• Flaig TW, Su LJ, Harrison G, Agarwal R, Glodé LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 1;120(9):2028-33. PubMed PMID: 17230508
• Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun;103(12):1729-37. PubMed PMID: 19220256
• Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 1;70(8):848-55. PubMed PMID: 20127732
• Li Y, Yang X, Su LJ, Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep. 2010 Oct;24(4):1019-28. PubMed PMID: 20811684
• Li Y, Yang X, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology. 2011 Jul;78(1):233.e7-13. PubMed PMID: 21529900
• Yang X, Bemis L, Su LJ, Gao D, Flaig TW. miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. Biores Open Access. 2012 Apr;1(2):55-62. PubMed PMID: 23514806
• Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res. 2013 Jan 1;19(1):148-57. PubMed PMID: 23172881
• Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, Serkova NJ, Li Y, Su LJ, Kessler E, Flaig TW. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS One. 2013 Sep 18;8(9):e74809. PubMed PMID: 24058630
• Cho SK, Emoto K, Su LJ, Yang X, Flaig TW, Park W. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J Biomed Nanotechnol. 2014 Jul;10(7):1267-76. PubMed PMID: 24804547
• Flaig TW, Salzmann-Sullivan M, Su LJ, Zhang Z, Joshi M, Gijón MA, Kim J, Arcaroli JJ, Van Bokhoven A, Lucia MS, La Rosa FG, Schlaepfer IR. Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget. 2017 Apr 21. doi: 10.18632/oncotarget.17359. [Epub ahead of print]. PMID: 28473655.
• Yang X, Su LJ, La Rosa FG, Smith EE, Schlaepfer IR, Cho SK, Kavanagh B, Park W, Flaig TW. The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model. Bladder Cancer. 2017 Jul 27;3(3):201-210. doi: 10.3233/BLC-170096. PMCID: PMC5545915.
• Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 Dec;17(4):1103-1108. PubMed PMID: 30289005
• Cho SK, Su LJ, Mao C, Wolenski CD, Flaig TW, Park W. Multifunctional nanoclusters of NaYF(4):Yb(3 ),Er(3 ) upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer. Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:784-792. PubMed PMID: 30678969
• Nordeen SK, Su LJ, Osborne GA, Hayman PM, Orlicky DJ, Wessells VM, van Bokhoven A, Flaig TW. Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. Life (Basel). 2021 Aug 27;11(9). PubMed PMID: 34575033